As the protection of your personal data is of particular concern to us, we only process your data based on legal provisions (EU GDPR 2018, DSG 1992 [SR235.1]). In this Privacy Statement, we inform you about the most important aspects of data processing in connection with our website.
By transferring your personal data to us and by using our website you confirm that you have read and understood this Privacy Statement.
If you use the contact form on our website or if you contact us by e-mail or telephone, we will process the data provided by you for the purpose of handling your inquiry and for potential follow-up questions; we will delete said data no later than three months after your inquiry has been dealt with. Moreover, your data will only be further processed if it is necessary due to statutory retention requirements or if it is necessary for maintaining and/or asserting any legal rights. Data is only disclosed to the extent that is required for the purposes mentioned above; as far as possible, data is only disclosed within our company.
Applications of any kind (job offers, internships, diploma theses, unsolicited job applications), which we receive by e-mail, including all data of the applicant and attachments, are only processed by the human resources department and the respective specialist department in order to assess if your profile fits one of our advertised job offers and/or if we will offer you a job that fits your profile. We also process your data for the initiation of an employment relationship with you, if applicable. Your data will be deleted no later than three months after the application procedure has been completed. Moreover, your data will only be further processed if it is necessary due to statutory retention requirements or if it is necessary for maintaining and/or asserting any legal rights. Data is only disclosed to the extent that is required for the purposes mentioned above; as far as possible, data is only disclosed within our company.
Our website uses so-called cookies. Cookies are small text files which your browser stores on your device. They cause no damage.
You can delete cookies from your device yourself at any time. Deleting or deactivating cookies may limit the functionality of our website.
Please note that Google Analytics is configured on this website in a way to ensure anonymous collection of IP addresses (IP masking). Your IP address is recorded but will be pseudonymized immediately. This allows for broad localization only.
You can subscribe to mailing list for media releases on our website. In order for you to subscribe, we need your e-mail address and your confirmation that you agree to receive the newsletter.
You can cancel the newsletter subscription at any time, by clicking on the unsubscribe link in the newsletter or by sending us an e-mail to: email@example.com. We subsequently delete your data in connection with the newsletter service immediately.
The General Data Protection Regulation provides you with rights of access, rectification, erasure, restriction, data portability, withdrawal and objection. If you believe that the processing of your data violates data protection law or if your rights under data protection law have been violated in any other way you can lodge a complaint with the supervisory authority. However, you may also contact us at any time using the contact details which can be found in our website’s ‘Contact’ section.
Data protection officer
You may contact our data protection officer by e-mail: firstname.lastname@example.org or by mail to the following address: PIQUR Therapeutics AG, Attn. Data protection officer, Hochbergerstrasse 60C, CH-4057 Basel, Switzerland
Date: 25 May 2018
No warranty and no liability
The material provided in this site is presented solely to improve public access to information about PIQUR Therapeutics AG.
PIQUR Therapeutics AG will make reasonable efforts to include accurate and current information, wherever possible, but makes no warranties or representations, expressed or implied, as to its accuracy or completeness. PIQUR Therapeutics AG will not be liable for any damages, including but not limited to special or consequential damages, that result from the use of, or the inability to use, the material contained in this site.
PIQUR Therapeutics AG may change the content of this site including the terms that govern the use of this site at any time without prior notice but does not assume any responsibility to update the information provided herein.
Forward looking information
Some of the statements on this site are forward looking. Such statements are inherently subject to known and unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of PIQUR Therapeutics AG and affiliates to be materially different from those expected or anticipated in the forward-looking statements.
PIQUR Therapeutics AG has no responsibility to update the forward-looking statements contained in this site to reflect events or circumstances occurring after the date of publication. You must not rely on this information for investment decisions.
Links to third party sites
Links to third party sites are provided for convenience only, and the inclusion of any links does not imply endorsement by PIQUR Therapeutics AG. The linked sites are not under control of PIQUR Therapeutics AG, and PIQUR Therapeutics AG disclaims any liability for all third party information and the use of it.
Restrictions on use and submissions
The contents of this site are owned and controlled by PIQUR Therapeutics AG. No use of any of these may be made without the prior written consent of PIQUR Therapeutics AG. All submissions communicated to PIQUR Therapeutics AG through this site shall be and remain PIQUR Therapeutics AG’s property. PIQUR Therapeutics AG will be entitled to use your submission for any commercial or other purpose whatsoever without paying any compensation to you. PIQUR Therapeutics AG will be under no obligation to treat your submission as confidential nor to respond to it. The pictures displayed on this website are subject to copyrights and may not be downloaded, copied, distributed or otherwise be used without prior permission of PIQUR Therapeutics AG.
Applicable law and jurisdiction
These terms shall be construed, enforced and performed in accordance with the substantive laws of Switzerland, without reference to the principles of conflicts of laws. The place of jurisdiction is Basel, Switzerland. PIQUR Therapeutics AG makes no representation that any information, materials or functions included are appropriate for use in any other jurisdiction. If you access this site you do so on your own initiative and are responsible for compliance with applicable local laws and regulations.
PIQUR Therapeutics AG
T +41 61 551 20 50
Highway A2 exit 1, along in direction Stücki/Kleinhüningen, you can drive up the ramp of the big grey building called Stücki Businesspark (next to the COOP gas station) and park right in front of the building or on the parking below.X
Bus no. 36 in direction Kleinhüningen, get off at bus-station «Hochbergerstrasse» (approx. 4 min.), follow driveway Hochbergerstrasse, after 150m on your right hand side you will see a big grey building called Stücki Business Park, go up the ramp and you find the entrance «C»X
Tram no. 2 in direction Eglisee, get off at tram-station «Basel Badischen Bahnhof» (approx. 10 min.), change and take bus no. 36 in direction Kleinhüningen, bus-stop «Hochbergerstrasse» (approx. 5 min.), follow driveway Hochbergerstrasse, after 150m on your right hand side you will see a big grey building called Stücki Business Park, go up the ramp and you find the entrance «C».X
PIQUR is located close to the centre of Basel on the north bank of the River Rhine, a few minutes from the borders of France and Germany. It is easily accessible by public transport from the two main railway stations and the airport.
The premises of PIQUR Therapeutics AG are located in the Technology Park Basel in the Stücki Business Park.X
PIQUR’s patent portfolio protects and covers a large area of lipid kinase and mTOR inhibitor patent space. PIQUR has created an intellectual property strategy that maximizes the protection of its technologies, knowhow and research areas of current and future interest. PIQUR’s differentiation against its peers is the outstanding industry expertise, the level of innovation with its unique, proprietary fragment and scaffold libraries and their best-in-class products with novel, balanced, dual-acting PI3K/mTOR inhibitors that fully address the given challenges, meeting therapeutic, tolerance and galenic needs.
One in every 2 men and one in every 3 women, living in the developed world, will develop cancer at some stage in their lives. In 2012, cancer accounted for 8 million deaths worldwide. Each cancer treatment remains a case-by-case battle, with a limited panel of therapeutic options available. Given the relatively small number of cancer treatments available today, the emergence of resistance usually means a poor prognosis. Thus, there is a tremendous need for new targeted therapies, based on new mechanisms of action and accompanied by a range of biomarker diagnostics for diagnosis, patient selection, therapy monitoring and follow up.
The PI3K-Akt-mTOR pathway is one of the three major cancer signalling pathways (Nature Rev. 2008). The PI3K/Akt/mTOR signalling pathway plays a critical role in the regulation of cancer cell growth, survival, and proliferation. The deregulation of this pathway is initiated by genetic mutations and amplifications, and is thought to be one of the most frequently mutated pathways in cancer. (Hennessy et al., 2005, Nat. Rev. Drug Discovery; Liu et al., 2009, Nat. Rev. Drug Discovery; Zoncu, R. et al., 2011, Nat. Rev. Mol. Cell Biol.).
PIQUR seeks to develop and market next generation medications for the treatment of cancer. To achieve this goal, PIQUR continues to expand on its strong product pipeline and has developed several proprietary methods for drug screening and identification
PIQUR has already identified a number of compounds that have desirable drug properties, both from a biological and a manufacturing perspective, forming the backbone of our pipeline.
PQR309: PIQUR’s lead compound, PQR309, is a novel, potent small molecule with strong, balanced pan-PI3K/mTOR selectivity. PQR309 compares favourably to current and clinically most advanced pan-PI3K inhibitors with respect to the off-target effects. PQR309 showed activity in different aggressive cancer cell lines inhibiting the PI3K pathway. In January 2014, PIQUR launched the clinical Phase 1 study in Europe with the PQR309 that was successfully concluded in Q2/2015. The initial results indicate that PQR309 is well-tolerated with no significant side effects and meets the primary endpoints of safety and tolerability. Furthermore, PQR309 demonstrated clear biologic activity and first promising signs of clinical activity in two advanced solid tumors patients with PI3K/mTOR alterations.
In addition to PQR309, PIQUR has several other compounds in preclinical development and late stage research in oncology, ophthalmology, dermatology and CNS disorders.